Literature DB >> 33098958

First case of molecularly identified and genetically characterized human T-cell leukemia virus type 2 infection in a pregnant woman in non-endemic Japan.

Madoka Kuramitsu1, Kazu Okuma2, Madoka Horiya3, Tsuyoshi Sekizuka4, Noriaki Kaneko5, Ema Saito5, Jun Sokunaga5, Makoto Kuroda4, Isao Hamaguchi1.   

Abstract

Human T-cell leukemia virus type 2 (HTLV-2) is non-endemic in Japan unlike the related HTLV type 1. Previously, although HTLV-2-seropositivity was identified via western blotting in one male blood donor in Japan, there have been no reports of HTLV-2 provirus detection by nucleic acid testing. In this report, one Japanese pregnant woman was clinically diagnosed as being HTLV-2-infected with a line immunoassay for specific antibodies after primary testing through prenatal screening in Japan. In genomic DNA of her peripheral blood mononuclear cells, HTLV-2 proviral genome was detected by nucleic acid testing (three methods) with quantitative polymerase chain reaction. The full-genome sequence of this strain was successfully determined. The identified virus was interestingly characterized as a presumed progenitor of subtypes a and c by recombination region and phylogenetic tree analyses. In conclusion, the present infection is, to our knowledge, the first case of molecularly identified and genetically characterized HTLV-2 infection found via prenatal screening in non-endemic Japan.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genome; HTLV-2; Japan; Pregnant woman; Provirus; Subtype

Year:  2020        PMID: 33098958     DOI: 10.1016/j.jviromet.2020.114005

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  1 in total

1.  Improvement of the understanding of blood donors with human T-cell leukaemia virus type 1 using a new information booklet.

Authors:  Hitomi Nakamura; Yasuko Sagara; Midori Yamamoto; Atae Utsunomiya; Toshiki Watanabe; Masahiro Satake; Kazuo Irita
Journal:  Transfus Med       Date:  2021-09-21       Impact factor: 2.057

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.